A Systematic Review and Meta-Analysis of the Association between Serotonergic Gene Polymorphisms and Obstructive Sleep Apnea Syndrome

Huajun Xu, Jian Guan*, Hongliang Yi, Shankai Yin*

Department of Otolaryngology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Otolaryngology Institute of Shanghai Jiao Tong University, Shanghai, China

Abstract

Background: 5-Hydroxytryptamine receptor (5-HTR) and 5-hydroxytryptamine transporter (5-HTT) gene polymorphisms have been reported to be associated with susceptibility to obstructive sleep apnea syndrome (OSAS). The associations, derived from sporadic, inconsistent, small-sample-size studies, need to be evaluated further in a meta-analysis.

Methods: Relevant studies were identified by searching PubMed, Embase, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu. Eligible data were extracted from each included study. Odds ratios (ORs) were calculated using a fixed-effects or a random-effects model. The ORs and 95% confidence interval (CI) were used to assess the strength of the association between serotonergic gene polymorphisms and OSAS in the dominant and recessive models, as well as alleles. The Q statistic was used to evaluate homogeneity and Begg’s test was used to assess publication bias.

Results: Eight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLPR), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk. The G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48–3.66), 1.24 (L vs. S, 95% CI: 1.04–1.49), and 2.87 (10 vs. 12, 95% CI: 1.38–5.97), respectively. These significant differences were determined in both dominant and recessive models. Of the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83–6.25) in a recessive model in male OSAS patients, but no significant association was found in females.

Conclusions: Our meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS. The A allele of the 1438G/A gene polymorphism is predominantly distributed in males and increased the OSAS risk significantly.

Introduction

Because of its high morbidity and mortality, obstructive sleep apnea syndrome (OSAS) has recently become an important public health issue. It affects about 2% of females and 4% of males in middle-aged groups in Western counties [1]. Repeated partial or complete collapse of the pharynx during sleep, which results in apnea or hypopnea associated with oxygen desaturation and arousal from sleep, is the most characteristic feature of OSAS [2]. The pathophysiology of OSAS is associated with activation of a number of neural, humoral, thrombotic, metabolic, and inflammatory disease mechanisms [3].

Serotonergic neurons innervating motoneurons increase their firing rates in response to respiratory challenges, and long-term facilitation of respiratory activity in response to hypoxia is 5-hydroxytryptamine (5-HT, serotonin)-dependent [4]. Thus, it is reasonable that the receptor and transporter of 5-HT are also involved in the pathophysiological process of OSAS.

There is a large family of 5-HT receptors [5]. Among them, 5-HTT receptor (5-HTR; 2A/2C) has been most studied. The 5-HTR 2A gene is located on chromosome 13q14–q21 and the 5-HTR 2C gene is located in the q24 region of chromosome X [6–7]. Binding with the 2A/2C receptors, 5-HT plays a vital role in preventing glossocoma and sustaining patency of the upper airway [8]. A series of case control studies reported an association between 5-HTR 2A/2C gene polymorphisms and OSAS [9–14]. In 5-HTR 2A, two polymorphisms have been reported: a 1438A/G polymorphism in the promoter region and an MspI polymorphic site at position 102T/C [12]. A 796C/G polymorphism locus in the 5-HTR 2C gene has also been identified [13].
The 5-HT transporter (5-HTT, serotonin transporter) gene is located in the 17q11.1–17q12 region of chromosome 17 [15]. Two gene polymorphisms, the 5-HTT gene-linked polymorphic region (5-HTTLPR) and the intron 2 variable numbers of tandem repeats (STin2VNTR), have been studied in connection with OSAS susceptibility because STin2VNTR can affect enhancer function and transcription of the 5-HTT gene and 5-HTTLPR can influence 5-HT reuptake [16–18].

Although the various studies have provided important serotonergic genetic information regarding susceptibility to OSAS [9–14,19,20], because of the limitations of small sample sizes in each study, low statistical power, and inconsistent results, they are incapable of demonstrating a reliable association. Also, the associations hinted at from sporadic cases and populations of differing ethnic origins need to be re-analyzed comprehensively. In this report, to further evaluate the associations between 5-HT receptor and transporter gene polymorphisms and the risk of OSAS, we performed a meta-analysis by combining the genotyping data from eligible studies published to date.

Materials and Methods

This study was strictly followed the guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis).

Publication Search

To identify all eligible studies that address the association between 5-HT receptor and transporter gene polymorphisms and OSAS, we conducted key word searches in the biomedical electronic databases, including PubMed, Embase, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu: (obstructive sleep apnea hypopnea syndrome or OSAS or obstructive sleep apnea syndrome or OSAS or obstructive sleep apnea or OS or sleep apnea or apnea) and (5-hydroxytryptamine receptor or 5-HT or serotonin receptor or 5-hydroxytryptamine transporter or 5-HTT or serotonin transporter) in combination with (gene or polymorphism or variants or alleles) were used as research terms. The final search was updated in June 2013. The search was limited to studies published in English and Chinese.

Inclusion and Exclusion Criteria

Case-control studies that met the following criteria were included: 1) published in peer-reviewed journals, 2) contained independent data, 3) had enough data to evaluate the relationship between gene polymorphisms and OSAS susceptibility, and 4) had enough data to determine the genotype distributions in both the case and control groups. The authors were contacted if there were queries regarding the studies. Studies were excluded for the following reasons: 1) lack of a suitable control group, 2) no usable data reported, 3) data were contradictory, 4) repeated data, and 5) abstracts or reviews.

Data Extraction

Two investigators (Drs. Xu and Guan) performed the data search, data screening, and data extraction independently. Disagreements regarding data screening and extraction were resolved by discussion. If there was still disagreement, a third reviewer (Prof. Yin) participated to resolve the issue. The following data were extracted from the original studies: first author, year of publication, country, sample size, age, gender, body mass index (BMI), apnea-hypopnea index (AHI), and genotype frequency.

Statistical Methods

The Review Manager software (ver. 5.0, Cochrane Collaboration, Oxford, UK), the SAS software (ver. 9.1.3, SAS Institute Inc., Cary, NC), and Stata (ver. 11.0, Stata Corporation, College Station, TX) were used for the meta-analysis and statistical analyses. For genetic frequency distributions, Hardy-Weinberg equilibrium (HWE) was calculated with the SAS software to assess goodness of fit. Homogeneity was tested using Cochran chi-squared tests. The Mantel-Haenszel fixed-effects model or the random-effects model was used for the meta-analysis in the comparison of serotonergic gene polymorphisms [21–22]. Begg’s test was used to evaluate publication bias.

Results

Search Results

In total, 52 studies were identified by electronic and manual searching. At the stage of screening by the inclusion criteria, 38 studies were excluded for the following reasons: animal studies, cell studies, reviews, or not correlated with OSAS. At the stage of screening by the exclusion criteria, after reading the full articles, six studies were excluded for the following reasons: two articles were repeated studies [23–24], one was an abstract [25], two articles lacked complete data [26–27], and one article had contradictory data [28]. Finally, eight studies met the exclusion criteria and were included in our systemic review and meta-analysis (Figure 1). Of the eight studies, six had data for 5-HTR2A 102 T/C, five for 5-HTR2A 1438 G/A, three for 5-HTTLPR, and three for STin2VNTR (Figure 1, Table S1).

Study Characteristics

All eligible studies were published between 2005 and 2013. Five studies were from China [10,13,14,19,20], one from Turkey [9], one from Brazil [11], and one from Japan [12] (Table S1). The studied populations were mainly middle-aged and slightly overweight in cases and controls, although one study lacked this information (Table S1). One study did not provide gender data [12]; the male proportion in the remaining populations ranged from 40.0% to 88.6% (Table S1). The BMI ranged from 21.3±7.5 kg/m² to 29.3±3.7 kg/m², although one study lacked these data [9]. The AHI of OSAS populations ranged from ≥5 to 53.9±16.4 times per h; the AHI of control groups were all below 5 (Table S1). All polymorphisms were identified by polymerase chain reaction (PCR) or PCR-restriction fragment length polymorphism (PCR-RFLP) techniques.

The allele frequencies of all OSAS and control samples were in HWE except one study (Table 1). The combined samples for 5-HT2A 102C/T [9–14], 5-HT2A 1438G/A [9–11,13,14], 5-HTTLPR [10,19,20], and STin2VNTR [10,19,20] polymorphisms for the meta-analysis in case and control groups were 566, 466, 593, and 593 and 728, 551, 479, and 479, respectively (Table S1).

Meta-analysis of the Association between 5-HTR and 5-HTT Gene Polymorphisms and OSAS

The association between gene polymorphisms and susceptibility to OSAS was evaluated in the total case and control populations combined from eligible studies of each gene locus. All genetic loci were tested in a dominant model, a recessive model, and a susceptibility allele versus insusceptibility allele model.

Of the 5-HTR2A 102T/C polymorphisms, six studies containing 566 case subjects and 728 controls were included in this meta-analysis [9–14]. The I² of the dominant models (TT+TC vs. CC), recessive model (TT vs. TC+CC) and T allele vs. C allele were 0
Figure 1. Flow chart of literature search and study selection. 6, 5, 3 and 3 studies were eligibly included in the meta-analysis of 5-HTR2A 102 T/C, 5-HTR2A 1438 G/A, HTTLRP and HTTVNTR, respectively. doi:10.1371/journal.pone.0086460.g001

| Table 1. Genotypes and alleles distribution in OSAS and control groups. |
|---------------------------------------------------------------|
| Study                  | Genotypes | Alleles | HWE |
|------------------------|------------|---------|-----|
|                        | OSAS       | Control | OSAS | Control |
| 102C/T                 |            |         | T    | C       |
| Bayazit Y, 2006 [9]    | 17         | 55      | 110 | 94      | Yes    |
| Chen H, 2013 [10]      | 34         | 124     | 112 | 98      | Yes    |
| De Carvalho T, 2013 [11]| 23        | 112     | 88  | 91      | No     |
| Sakai K, 2005 [12]     | 47         | 184     | 170 | 96      | Yes    |
| Yin G, 2012 [13]       | 72         | 252     | 168 | 101     | Yes    |
| Zhu J, 2007 [14]       | 18         | 66      | 64  | 50      | Yes    |
| 1438G/A                |            |         | A    | G       |
| Bayazit Y, 2006 [9]    | 24         | 67      | 100 | 104     | Yes    |
| Chen H, 2013 [10]      | 74         | 178     | 84  | 126     | Yes    |
| De Carvalho T, 2013 [11]| 35        | 131     | 69  | 91      | No     |
| Yin G, 2012 [13]       | 85         | 252     | 168 | 101     | Yes    |
| Zhu J, 2007 [14]       | 41         | 97      | 33  | 64      | Yes    |
| 5-HTTLPR               |            |         | S    | L       |
| Chen H, 2013 [10]      | 59         | 158     | 84  | 146     | Yes    |
| Yue W, 2005 [20]       | 51         | 135     | 73  | 210     | Yes    |
| Yue W, 2008 [19]       | 114        | 334     | 174 | 477     | Yes    |
| STin2VNTR              | 10/10      | 10/12   | 12/12| 10/10   | Yes    |
| Chen H, 2013 [10]      | 8          | 64      | 178 | 12      | 98     |
| Yue W, 2005 [10]       | 3          | 26      | 182 | 16      | Yes    |
| Yue W, 2008 [19]       | 6          | 58      | 450 | 47      | Yes    |

Abbreviation: OSAS, obstructive sleep apnea syndrome; NM, not mentioned; S/L allele, short/long allele; 5-HTTLPR, 5-HT gene-linked polymorphic region; STin2VNTR, serotonin transporter intron 2 variable number tandem repeat; HWE, Hardy–Weinberg equilibrium.

doi:10.1371/journal.pone.0086460.g001
and the p values of the Q test were higher than 0.1, suggesting no significant heterogeneity among the studies, so we used a fixed-effects model to analyze the data. As shown in Table 2, meta-analysis of the dominant model (TT + TC vs. CC), recessive model (TT vs. TC + CC), and T allele vs. C allele revealed that no genotype or allele was associated with OSAS risk (Table 2, Figure 2A, B, C).

For the 5-HTR2A 1438G/A polymorphism, five studies had 466 case subjects and 551 controls [9–11,13,14]. The I² of the dominant models (AA + AG vs. GG) and the A allele vs. G allele were over 50%, and the p values of the Q test were 0.47 and <0.01, respectively, suggesting strong heterogeneity among the studies. So, these data were analyzed using a random-effects model. The meta-analysis revealed that the A allele was associated with OSAS risk with an OR of 2.44 (95% CI: 1.11–5.30) in the dominant model (AA + AG vs. GG). The A allele increased the OSAS risk with an OR of 2.33 (95% CI: 1.48–3.66) compared with the G allele (Table 2, Figure 2D, F). The I² of the recessive model (AA vs. AG + GG) was 0 and the p value of the Q test was less than 0.01, so we used a fixed-effects model to analyze the data.

Figure 2. Forest plots for the associations between 5-HTR2A 102 T/C, 5-HTR2A 1438 G/A, HTTLRP and HTTVNTR gene polymorphisms and OSAS risk. The squares correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0086460.g002
As shown in Table 2 and Figure 2E, the A allele was associated with a greater OSAS risk with an OR of 3.31 (95% CI: 2.48–4.40) in the recessive model (AA vs. AG+GG).

Of the long or short 5-HTTLPR, three studies were pooled for totals of 593 and 479 subjects in the OSAS and control groups [10,19,20], respectively. The I² of the dominant model (LL vs. LS) was 0% and the p values of the Q test were all more than 0.1. Meta-analysis with a fixed-effects model showed that the LL genotype increased the OSAS risk at an OR of 2.87 (95% CI: 1.38–5.97) compared with 12 tandem repeats (Table 2, Figure 2H).

For the STin2VNTR gene polymorphism, three studies were pooled with 593 and 479 subjects in the OSAS and control groups, respectively [10,19,20]. The I² of the dominant model (10/10+10/12 vs. 12/12) and recessive model (10/10 vs. 10/12+12/12), were 5 and 0, and the p values of the Q test were 0.95 and 0.01, respectively. Meta-analysis using a fixed-effects model showed that 10 tandem repeats increased the OSAS risk with an OR of 2.13 (95% CI: 1.53–2.96) and 4.10 (95% CI: 1.48–11.35) in a dominant model (10/10 vs. 10/12+12/12), respectively (Table 2, Figure 2J, K). The 10 tandem repeats variant increased the OSAS risk at an OR of 2.87 (95% CI: 1.38–5.97) compared with 12 tandem repeats (Table 2, Figure 2L).

Table 2. Meta-analysis of the association between gene polymorphisms and OSAS risk.

| Polymorphism          | Genotypes      | No. | Test of association | Test of heterogeneity |
|-----------------------|----------------|-----|---------------------|-----------------------|
|                       |                |     | OR                  | 95% CI                | P value | Model | Q     | P value | I²     |
| 102T/C                | TT+TC vs.CC    | 6   | 0.90                | 0.69–1.19             | 0.47    | F     | 4.67  | 0.46    | 0      |
|                       | TT vs. TC+CC   | 6   | 1.02                | 0.79–1.32             | 0.86    | F     | 1.06  | 0.96    | 0      |
|                       | T allele vs. C allele | 5 | 1.00                | 0.83–1.20             | 0.98    | F     | 1.74  | 0.78    | 0      |
| 1438G/A               | AA+AG vs. GG   | 5   | 2.44                | 1.11–5.38             | 0.03    | R     | 20.76 | 0.47    | 81     |
|                       | AA vs. AG+GG   | 5   | 3.31                | 2.48–4.40             | <0.01   | F     | 3.53  | <0.01   | 0      |
|                       | A allele vs. G allele | 5 | 2.33                | 1.48–3.66             | <0.01   | F     | 22.96 | <0.01   | 83     |
| 5-HTTLPR L/S          | LL+SL vs. SS  | 3   | 1.22                | 0.96–1.55             | 0.11    | F     | 0.24  | 0.86    | 0      |
|                       | LL vs. SL+SS   | 3   | 1.52                | 1.07–2.16             | 0.02    | F     | 0.31  | 0.88    | 0      |
|                       | L allele vs. S allele | 3 | 1.24                | 1.04–1.49             | 0.02    | F     | 0.02  | 0.99    | 0      |
| STin2VNTR 10/12       | 10/10+10/12 vs.12/12 | 3 | 2.13                | 1.53–2.96             | <0.01   | F     | 2.1   | 0.35    | 5      |
|                       | 10/10 vs.10/12+12/12 | 3 | 4.10                | 1.48–11.35            | <0.01   | F     | 0.65  | 0.72    | 0      |
|                       | 10 allele vs. 12 allele | 3 | 2.87                | 1.38–5.97            | <0.01   | R     | 10.18 | <0.01   | 80     |

Abbreviation: L or S, long or short 5-HTT gene-linked polymorphic region;10 or 12, serotonin transporter intron 2 variable number tandem repeat; F, fixed-effects model; R, random-effects model; OR, odds ratios; 95%CI, 95% confidence interval.

doi:10.1371/journal.pone.0086460.002

Discussion

Although the genetic basis of OSAS is poorly understood, studies to date have focused on relationships between gene polymorphisms and susceptibility to OSAS [9–14,19,20,29]. Among genetic variants, polymorphisms in 5-HTR and 5-HTT have been investigated most frequently. Thus, the associations suggested from sporadic, inconsistent, small-sample-size studies needed to be further evaluated in a systematic review and meta-analysis. In this report, the combined number of samples for 5-HT2A 102C/T, 5-HTTLPR L/S, and STin2VNTR 10/12 polymorphisms showed no significant difference between males and females (Table 3), while the AA genotype of 5-HT2A 1438G/A in males was significantly more common than in females. The AA genotype increased the OSAS risk with an OR of 4.21 (95% CI: 2.83–6.25) in a recessive model in male OSAS patients; however no significant association was found in females (Figure 3, Table 3).

Publication Bias

Begg’s test was used to evaluate publication bias in the literature. The shapes of the funnel plots revealed no obvious asymmetry (not shown). We then used Begg’s test to assess statistical evidence of funnel plot symmetry, but no significant publication bias was indicated (Table 4).

Table 3. Study characteristics and meta-analysis results for 5-HT2A 102C/T, 5-HTTLPR L/S, and STin2VNTR 10/12 polymorphisms.

| Polymorphism          | Genotypes      | No. | Test of association | Test of heterogeneity |
|-----------------------|----------------|-----|---------------------|-----------------------|
|                       |                |     | OR                  | 95% CI                | P value | Model | Q     | P value | I²     |
| 102T/C                | TT+TC vs.CC    | 6   | 0.90                | 0.69–1.19             | 0.47    | F     | 4.67  | 0.46    | 0      |
|                       | TT vs. TC+CC   | 6   | 1.02                | 0.79–1.32             | 0.86    | F     | 1.06  | 0.96    | 0      |
|                       | T allele vs. C allele | 5 | 1.00                | 0.83–1.20             | 0.98    | F     | 1.74  | 0.78    | 0      |
| 1438G/A               | AA+AG vs. GG   | 5   | 2.44                | 1.11–5.38             | 0.03    | R     | 20.76 | 0.47    | 81     |
|                       | AA vs. AG+GG   | 5   | 3.31                | 2.48–4.40             | <0.01   | F     | 3.53  | <0.01   | 0      |
|                       | A allele vs. G allele | 5 | 2.33                | 1.48–3.66             | <0.01   | F     | 22.96 | <0.01   | 83     |
| 5-HTTLPR L/S          | LL+SL vs. SS  | 3   | 1.22                | 0.96–1.55             | 0.11    | F     | 0.24  | 0.86    | 0      |
|                       | LL vs. SL+SS   | 3   | 1.52                | 1.07–2.16             | 0.02    | F     | 0.31  | 0.88    | 0      |
|                       | L allele vs. S allele | 3 | 1.24                | 1.04–1.49             | 0.02    | F     | 0.02  | 0.99    | 0      |
| STin2VNTR 10/12       | 10/10+10/12 vs.12/12 | 3 | 2.13                | 1.53–2.96             | <0.01   | F     | 2.1   | 0.35    | 5      |
|                       | 10/10 vs.10/12+12/12 | 3 | 4.10                | 1.48–11.35            | <0.01   | F     | 0.65  | 0.72    | 0      |
|                       | 10 allele vs. 12 allele | 3 | 2.87                | 1.38–5.97            | <0.01   | R     | 10.18 | <0.01   | 80     |
in male OSAS patients; however no significant association was found in the female population. Other gene polymorphisms, such as 5-HTR2A 1438 G/A, failed in the meta-analysis due to the limitations of eligible studies or insufficient data. We attempted to categorize the data according to BMI, AHI, and gender to further evaluate the association between gene polymorphisms and OSAS. However, this was not possible due to the limited quantity of data available.

Although race is a major factor in the distribution of gene polymorphisms, and our study data were from Japan [12], China [10,14,19,20], Turkey [9], and Brazil [11], we found no distribution differences in the gene polymorphisms evaluated. We could not conduct a haplotype analysis in this study because we

![Figure 3. Forest plots for the association between 5-HTR2A 1438 G/A and OSAS risk in male and female groups. The squares correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. doi:10.1371/journal.pone.0086460.g003](image)

Table 3. Genotype distribution of 5-HTR 2A and 5-HTT gene polymorphisms in OSAS patients subgrouped by gender.

| Study                  | Male | Female | Chi-square with Yates' correction | Two-tailed p value |
|------------------------|------|--------|-----------------------------------|-------------------|
| 102C/T                 |      |        |                                   |                   |
| Bayazit Y, 2006 [9]    | 8    | 25     |                                   |                   |
| De Carvalho T, 2013    | 9    | 64     |                                   |                   |
| Pooled                 | 17 (16%) | 89 (84%) | 11 (22.4%) | 38 (77.6%) | 0.548 | 0.459 |
| 1438G/A                |      |        |                                   |                   |
| Bayazit Y, 2006 [9]    | 19   | 14     |                                   |                   |
| Chen H,2013 [10]       | 65   | 34     |                                   |                   |
| De Carvalho T, 2013    | 33   | 40     |                                   |                   |
| Zhu J,2007 [14]        | 36   | 18     |                                   |                   |
| Pooled                 | 153 (59.1%) | 106 (40.9%) | 21 (25.6%) | 61 (74.4%) | 25.586 | <0.0001 |
| 5-HTTLPR L/S           |      |        |                                   |                   |
| Yue W, 2008 [19]       | 30   | 190    | 4 (11.8%) | 30 (88.2%) | 0.001 | 0.978 |
| STin2VNTR 10/12        | 10/10 | 12/12+10/12 | 10/10 | 12/12+10/12 |                      |
| Yue W, 2008 [19]       | 4 (1.8%) | 216 (98.2%) | 2 (5.9%) | 32 (94.1%) | 0.715 | 0.398 |

Abbreviation: 5-HTTLPR L/S, L or S, long or short 5-HTT gene-linked polymorphic region; STin2VNTR 10/12, 10 or 12, serotonin transporter intron 2 variable number tandem repeat. The genotype distribution was expressed as frequency or frequency with percentage.
doi:10.1371/journal.pone.0086460.t003
Table 4. Tests for publication bias in overall population.

| Polymorphism | Comparrison | P value |
|--------------|-------------|---------|
| 102T/C       | TT+TC vs.LC | 0.71    |
|              | TT vs. TC+CC| 0.71    |
| T allele vs. C allele | 0.73 |
| 1438G/A     | AA+AG vs. GG| 0.81 |
|             | AA vs. AG+GG| 0.81 |
|             | A allele vs. G allele | 0.81 |
| 5-HTTLPR L/S | LL+SL vs. SS | 1.00 |
|             | LL vs. SL+SS | 1.00 |
|             | L allele vs. S allele | 1.00 |
| STin2VNTR 10/12 | 10/10 vs. 10/12 vs. 12/12 | 1.00 |
|             | 10/10 vs. 10/12+12/12 | 1.00 |
|             | 10/10 allele vs. 12/12 allele | 1.00 |

Abbreviation: 5-HTTLPR L/S, long or short 5-HT gene-linked polymorphic region; STin2VNTR 10/12, 10 or 12 tandem repeats of serotonin transporter intron 2 variable number tandem repeat.

doi:10.1371/journal.pone.0086460.t004

could not collect original haplotype data. For the 5-HTR2A 1438G/A and STin2VNTR meta-analyses, heterogeneity existed among the studies included, which, together with the analysis of the genotype distribution of 5-HTR 2A and 5-HTT gene polymorphisms according to gender, suggests that the heterogeneity may have been caused by gender imbalances in the different studies.

During the preparation of this manuscript, a systematic review and meta-analysis of the association between 5-HT2A receptor polymorphisms and risk of OSAS was published [30]. The differences between this report and our study are as follows: our study included not only 5-HT gene polymorphisms but also 5HTTLPR and STin2VNTR gene polymorphisms, and our study first demonstrated that gender was an important cofactor for 1438G/A allele distribution; the AA genotype increased the OSAS risk with an OR of 4.21 (95% CI: 2.83–6.25) in a recessive model in male OSAS patients, but no significant association was found in females. Further studies using larger samples, of better designs, and that include additional ethnicities are warranted. Additionally, the biological mechanism(s) and function(s) of the 5-HT and 5-HTT genotypes and haplotypes in the pathogenesis of OSAS should be investigated further.

Supporting Information
Table S1 Characteristics summary of publications included in meta-analysis. (XLS)
Checklist S1 PRISMA Checklist. (DOC)

Author Contributions
Conceived and designed the experiments: JG SY. Performed the experiments: HX HY. Analyzed the data: HX JG HY SY. Contributed reagents/materials/analysis tools: HX JG HY SY. Wrote the paper: HX JG.

References
1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, et al. (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med, 328: 1230–1235.
2. Eckert DJ, Malhotra A (2008) Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc, 5: 144–153.
3. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI (2008) Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med, 4: 261–272.
4. Hilaire G, Voituron N, Menuet C, Ichiyama RM, Subramanian HH, et al. (2010) The role of serotonin in respiratory function and dysfunction. Respir Physiol Neurobiol, 174: 76–88.
5. Sood S, Liu X, Liu H, Horner RL (2007) Genioglossus muscle activity and serotonergic modulation of hypoglossal motor output in obese Zucker rats. J Appl Physiol, 102: 2240–2250.
6. Veasey SC (2003) Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am J Respir Med, 2: 21–29.
7. Masuda K, Hashizume C, Ogata N, Kikusui T, Takeuchi Y, et al. (2004) Sequencing of canine 5-hydroxytryptamine receptor(5-HTR) 1B, 2A, 2C genes and identification of polymorphisms in the 5-HTR1B gene. J Vet Med Sci, 66: 965–972.
8. Bayazit YA, Yilmaz M, Cilteci T, Erdal E, Kokturk O, et al. (2006) Association of the -1438G/A polymorphism of the 5-HT2A receptor gene with obstructive sleep apnea syndrome. ORI, J Otorhinolaryngol Relat Spec, 68: 123–128.
9. Chen H, Hu K, Zhu J, Xianyu Y, Cao X, et al. (2013) Polymorphisms of the 5-hydroxytryptamine 2A/2C receptor genes and 5-hydroxytryptamine transporter gene in Chinese patients with OSAHS. Sleep Breath, Mar 14.
10. de Carvalho TB, Suman M, Molina FD, Piatto VB, Maniglia JV (2013) Relationship of obstructive sleep apnea syndrome with the 5-HT2A receptor gene in Brazilian patients. Sleep Breath, 17: 57–62.
11. Sakai K, Takada T, Nakayama H, Kubota Y, Nakamura M, et al. (2005) Serotonin-2A and 2C receptor gene polymorphisms in Japanese patients with obstructive sleep apnea. Intern Med, 44: 928–933.
12. Yao G, Ye J, Han D, Zhang Y, Zeng W, et al. (2012) Association of the 5-HT2A receptor gene polymorphisms with obstructive sleep apnea hypopnea syndrome in Chinese Han population. Acta Otolaryngol, 132: 203–209.
13. Zhu JY, Hu K, Ma ZN, Liu D (2007) The association between polymorphism of the serotonin 2A, 2C receptor genes and obstructive sleep apnea-hypopnea syndrome in Han population. Zhonghua Jie He He Hu Xi Za Zhi, 30: 912–917, Chinese.
14. Esterling LE, Yoshikawa T, Turner G, Badner JA, Bengel D, et al. (1998) Serotonin transporter (5-HTT) gene and bipolar affective disorder. Am J Med Genet, 81: 37–40.
15. Heils A, Teufel A, Petri S, Stober G, Riederer P, et al. (1996) Allelic variation of the human serotonin transporter gene expression. J Neurochem, 66: 2621–2624.
17. Lesch KP, Bengel D, Heils A, Sahel SZ, Greenberg BD, et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274: 1527–1531.
18. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, et al. (1999) Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet, 88: 83–87.
19. Yue W, Liu H, Zhang J, Zhang X, Wang X, et al. (2000) Association study of serotonin transporter gene polymorphisms with obstructive sleep apnea syndrome in Chinese Han population. Sleep, 31: 1535–1541.
20. Yue WH, Liu PZ, Hao W, Zhang XH, Wang XP, et al. (2005) Association study of sleep apnea syndrome and polymorphisms in the serotonin transporter gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 22: 533–536. Chinese.
21. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22: 719–748.
22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials, 7: 177–188.
23. Zhu J, Zeng YQ, Shi MJ, Hu K, Chen G (2008) Association between obstructive sleep apnea-hypopnea syndrome and A1438G polymorphism of serotonin 2A receptor gene. International Journal of Respiratory, 28: 142–145. Chinese.
24. Piatto VB, Carvalho TB, De Marchi NS, Molina FD, Maniglia JV (2011) Polymorphisms in the 5-HT2A gene related to obstructive sleep apnea syndrome. Braz. J Otorhinolaryngol., 77: 348–355.
25. Maia S, Carvalho C, Leal R, Martinsda Silva A, Lopes J, et al. (2010) The serotonin HTR2A receptor 102 T>C gene polymorphism may play a role in the susceptibility to sleep disorders in the Portuguese population. Journal of Sleep Research, 19: 130. Abstract.
26. Larkin EK, Patel SR, Goodloe RJ, Li Y, Zhu X, et al. (2010) A candidate gene study of obstructive sleep apnea in European Americans and African Americans. Am J Respir Crit Care Med, 182: 947–953.
27. Schroeder CM, Primeau MM, Hallmayer JF, Lazzaroni LC, Hubbard JT, et al. (2013) Serotonin transporter polymorphism is associated with increased apnea-hypopnea index in older adults. Int J Geriatr Psychiatry, Jun 11.
28. Yilmaz M, Bayazit YA, Ciftci TU, Erthal ME, Urban M, et al. (2005) Association of serotonin transporter gene polymorphism with obstructive sleep apnea syndrome. Laryngoscope, 115: 832–836.
29. Palmer LJ, Bushbaum SG, Larkin EK, Patel SR, Elston RC, et al. (2003) Whole genome scan for obstructive sleep apnea and obesity. Am J Hum Genet, 72: 340–350.
30. Zhao Y, Tao L, Nie P, Lu X, Xu X, et al. (2013) Association between 5-HT2A receptor polymorphisms and risk of obstructive sleep apnea and hypopnea syndrome: A systematic review and meta-analysis. Gene, Aug 26.
31. Sorlí JV, Francés F, González JI, Guillén M, Porrós O, et al. (2008) Impact of the -1438G>A polymorphism in the serotonin 2A receptor gene on anthropometric profile and obesity risk: A case–control study in a Spanish Mediterranean population. Appetite, 50: 260–265.